Table 1.
Correlation between TLR4 and PD-L1 expression and various clinicopathological features
| Characteristics | Cases, N (%) | TLR4 | P-value | PD-L1 | P-value | ||
|---|---|---|---|---|---|---|---|
| Low | High | Low | High | ||||
| Age (years) | |||||||
| <60 | 89 (61.8) | 53 (59.6) | 36 (40.4) | 0.706 | 50 (56.1) | 39 (43.8) | 0.537 |
| ≥60 | 55 (38.2) | 31 (56.4) | 24 (43.6) | 28 (50.9) | 27 (49.1) | ||
| Gender | |||||||
| Male | 93 (64.6) | 52 (55.9) | 41 (44.1) | 0.426 | 55 (59.1) | 38 (40.9) | 0.744 |
| Female | 51 (35.4) | 32 (62.7) | 19 (37.3) | 23 (29.5) | 28 (42.4) | ||
| Histological type | |||||||
| PTCL-NOS | 17 (11.8) | 7 (41.2) | 10 (58.8) | 0.203 | 7 (41.2) | 10 (58.8) | 0.148 |
| AITL | 88 (61.1) | 53(60.2) | 35 (39.8) | 44 (50.0) | 44 (50.0) | ||
| ALK+ ALCL | 20 (13.9) | 10 (50.0) | 10 (50.0) | 14 (70.0) | 6 (30.0) | ||
| ALK− ALCL | 19 (13.2) | 14 (73.7) | 5 (26.3) | 13 (68.4) | 6(31.6) | ||
| Primary site | |||||||
| Nodal | 116 (80.5) | 74 (63.8) | 42 (36.2) | 0.007 | 65 (56.1) | 51 (43.9) | 0.360 |
| Extranodal | 28 (19.5) | 10 (35.7) | 18 (64.3) | 13 (46.4) | 15 (53.6) | ||
| Tumor size | |||||||
| <7.5 cm | 133 (92.3) | 76 (57.1) | 57 (42.9) | 0.314 | 69 (51.9) | 64 (48.1) | 0.055 |
| ≥7.5 cm | 11 (7.7) | 8 (72.7) | 3 (27.3) | 9 (81.8) | 2 (18.2) | ||
| No. of extranodal involvement(s) | |||||||
| 0–1 | 15 (10.4) | 11 (73.3) | 4 (26.7) | 0.213 | 12 (80.0) | 3 (20.0) | 0.034 |
| >1 | 129 (89.6) | 73 (56.6) | 56 (43.4) | 66 (51.2) | 63 (48.8) | ||
| Ann Arbor stage | |||||||
| I–II | 39 (27.1) | 28 (71.8) | 11 (28.2) | 0.039 | 23 (58.9) | 16 (41.0) | 0.480 |
| III–IV | 105 (72.9) | 56 (53.3) | 49 (46.7) | 55 (52.4) | 50 (47.6) | ||
| B symptoms | |||||||
| Absent | 63 (43.7) | 32 (38.1) | 31 (51.7) | 0.106 | 29 (46.1) | 34 (53.9) | 0.084 |
| Present | 81 (56.3) | 52 (61.9) | 29 (48.3) | 49 (60.5) | 32 (39.5) | ||
| ECOG score | |||||||
| 0–1 | 127 (88.2) | 73 (57.5) | 54 (42.5) | 0.266 | 68 (53.5) | 59 (46.5) | 0.682 |
| 2–4 | 17 (11.8) | 11 (64.7) | 6 (35.3) | 10 (58.2) | 7 (41.2) | ||
| IPI score | |||||||
| Lower | 96 (66.7) | 56 (58.3) | 40 (41.7) | 1.000 | 51 (53.1) | 45 (46.9) | 0.723 |
| Higher | 48 (33.3) | 28 (58.3) | 20 (41.7) | 27 (56.2) | 21 (43.8) | ||
| LDH levels (U/L) | |||||||
| <250 U | 75 (52.1) | 42 (56.0) | 33 (44.0) | 0.637 | 41 (17.1) | 34 (82.9) | 0.900 |
| ≥250 | 69 (47.9) | 42 (60.9) | 27 (39.1) | 37 (53.6) | 32 (46.4) | ||
| HGB levels (g/L) | |||||||
| <120 | 42 (29.2) | 21 (50.0) | 21 (50.0) | 0.005 | 19 (45.2) | 23 (54.8) | 0.168 |
| ≥120 | 102 (70.8) | 63 (61.8) | 39 (38.2) | 59 (57.5) | 43 (42.5) | ||
| PLT count (10^9/L) | |||||||
| <100 | 9 (6.3) | 5 (55.6) | 4 (44.4) | 0.654 | 8 (88.9) | 1 (11.1) | 0.031 |
| ≥100 | 134 (93.7) | 79 (58.2) | 56 (41.8) | 70 (51.5) | 65 (48.5) | ||
| Leukocyte count (10^9/L) | |||||||
| <7.20 | 68 (47.2) | 37 (54.4) | 31 (45.6) | 0.367 | 36 (52.9) | 32 (47.1) | 0.780 |
| ≥7.20 | 76 (52.8) | 47 (61.8) | 29 (38.2) | 42 (55.3) | 34 (44.7) | ||
| Ki-67 (%) | |||||||
| <60 | 84 (58.3) | 48 (57.1) | 36 (42.9) | 0.732 | 50 (59.5) | 34 (40.5) | 0.127 |
| ≥60 | 60 (41.7) | 36 (60.0) | 24 (40.0) | 28 (46.7) | 32 (53.3) | ||
Abbreviations: AITL, angioimmunoblastic T-cell lymphoma; ALCL, anaplastic large cell lymphoma; IPI, international prognostic index; LDH, lactate dehydrogenase; PD-L1, programmed cell death-ligand 1; PTCL-NOS, peripheral T-cell lymphomas not otherwise specified; TLR4, toll-like receptor 4.